Adaptimmune therapeutics plc ( afami-cel ) is a cell therapy company that has received tremendous support for afami-cel from healthcare providers and patients. in 2022, we are focused on four things to drive value for our stakeholders : one submitting the biomarker for afami-cel in the second quarter of this year ; two  building out the moage-a4 franchise with scaling up our manufacturing capabilities ; and four advancing our allogeneic platform. we are working with our management team and we are carefully managing investments for near and long - term success. we are well positioned to weather the current economic environment and emerge as one of the few cell therapy companies with commercial products and an exciting clinical pipeline against solid tumors. we are well positioned to weather our current economic environment and emerge as one of the Few cell therapy companies with commercial products and an exciting trial pipeline against solid tumors. we are being well positioned to weather the current economic environment with an exciting clinical pipeline against solid tumors, and we are well positioned to weather the current economy and emerge as one of the few cell therapy businesses with commercial products and an exciting clinical pipeline against Solid tumors. we are well positioned for weathering the current economic environment and emerge as one of three cell therapy companies with commercial products and an exciting cell pipeline against solid tumors. we are now well positioned to weather the current economic environment, emerge as one of the few cell therapy companies and an exciting clinical pipeline against solid tumors.we will continue to prioritize our spending and ensure success across the four focus areas.